Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;17(12):1713-1715.
doi: 10.2215/CJN.12491022. Epub 2022 Nov 21.

Bardoxolone Methyl for Alport Syndrome: Opportunities and Challenges

Catherine Quinlan  1   2   3   4 , Kushani Jayasinghe  2   4   5   6
Affiliations
Editorial

Bardoxolone Methyl for Alport Syndrome: Opportunities and Challenges

Catherine Quinlan et al. Clin J Am Soc Nephrol. 2022 Dec.
No abstract available

Keywords: Alport syndrome; bardoxolone; clinical trial; genetic kidney disease; hematuria; proteinuria; therapy.

PubMed Disclaimer

Comment on

  • Effects of Bardoxolone Methyl in Alport Syndrome.
    Warady BA, Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Kashtan CE, Knebelmann B, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Rheault MN, Silva AL, Stenvinkel P, Torra R, Chertow GM. Warady BA, et al. Clin J Am Soc Nephrol. 2022 Dec;17(12):1763-1774. doi: 10.2215/CJN.02400222. Epub 2022 Nov 21. Clin J Am Soc Nephrol. 2022. PMID: 36411058 Free PMC article. Clinical Trial.

References

    1. Daga S, Ding J, Deltas C, Savige J, Lipska-Ziętkiewicz BS, Hoefele J, Flinter F, Gale DP, Aksenova M, Kai H, Perin L, Barua M, Torra R, Miner JH, Massella L, Ljubanović DG, Lennon R, Weinstock AB, Knebelmann B, Cerkauskaite A, Gear S, Gross O, Turner AN, Baldassarri M, Pinto AM, Renieri A: The 2019 and 2021 international workshops on Alport syndrome. Eur J Hum Genet 30: 507–516, 2022 - PMC - PubMed
    1. Quinlan C, Rheault MN: Genetic basis of type IV collagen disorders of the kidney. Clin J Am Soc Nephrol 16: 1101–1109, 2021. 10.2215/CJN.19171220 - DOI - PMC - PubMed
    1. Kashtan CE, Gross O: Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-An update for 2020. Pediatr Nephrol 36: 711–719, 2021 - PubMed
    1. Gross O, Tönshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Zappel H, Hoyer P, Staude H, König S, John U, Gellermann J, Hoppe B, Galiano M, Hoecker B, Ehren R, Lerch C, Kashtan CE, Harden M, Boeckhaus J, Friede T, Koziolek M, Bramlage CP, Weber F, Albrecht-Nock T, Sonntag J, Frese J, Kettwig M, Hilgers R, Hansen M, Wedekin M, Meyer N, Klaiber S, Gessner M, Liebau M, Vogt-Weigeldt A-K, Jungraithmayr T, Ponsel S, Jacoby U, Konrad M, Kranz B, Koenig J, Loechtermann L, Pohl M, Husain R, Mueller K, Thumfart J, Schalk G, Feldkoetter M, Schmidt S, Sauerstein K, Muschiol E, Billing H, Wilkening F; German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators : A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 97: 1275–1286, 2020 - PubMed
    1. Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group : DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 29: 2745–2754, 2018 - PMC - PubMed